Could HBOT Help With Tinnitus? What We Know So Far
By OxyPlus - Newcastle's Specialist Hyperbaric Oxygen Therapy Clinic oxyplus.co.uk | Updated July2026 | 8 min read
Tinnitus, the persistent ringing, buzzing, hissing, or whistling sound that exists only in your head, affects an estimated 15% of the global population. For most people it is manageable background noise. For around 1–2% of the population, it is severely debilitating: disrupting sleep, concentration, and mood in ways that profoundly affect quality of life.
What makes tinnitus so frustrating, both to live with and to treat, is that conventional medicine has remarkably little to offer. There is no widely effective pharmaceutical treatment. Cognitive Behavioural Therapy can help with the distress it causes, but does not address the sound itself. Many people with tinnitus are told, essentially, to learn to live with it.
At OxyPlus, our hyperbaric oxygen therapy clinic in Newcastle, we are asked about tinnitus regularly, and the question deserves a careful, honest answer. The evidence picture for HBOT and tinnitus is nuanced. It is strongest for a specific, time-sensitive type of hearing loss with which tinnitus is frequently associated. It is more limited, though mechanistically plausible, for chronic tinnitus without an acute triggering event.
This post explains what tinnitus actually is, what the research on HBOT shows, where it is most likely to help, and how timing affects your options.
What Is Tinnitus and What Causes It?
Tinnitus is not a disease in itself, it is a symptom, and it can arise from multiple underlying mechanisms. The mechanisms underlying tinnitus are multifactorial and not fully understood. Proposed pathophysiological processes include cochlear hair cell damage, aberrant auditory cortical activity, and impaired cochlear microcirculation.
In practical terms, the most common causes and associations include:
Noise-induced hearing loss — damage to the delicate hair cells of the cochlea from prolonged or sudden loud noise exposure. This is the most common cause of tinnitus and is often permanent.
Sudden sensorineural hearing loss (SSNHL) — a rapid, unexplained loss of hearing (defined as 30 dB or more across three frequencies within 72 hours) that is very frequently accompanied by tinnitus. SSNHL is frequently accompanied by tinnitus and/or vertigo.
Vascular and circulatory factors — reduced blood flow to the cochlea, small vessel disease, or ischaemia affecting the inner ear structures.
Age-related hearing decline — presbycusis, the gradual loss of hearing with age, is often associated with tinnitus.
Central auditory processing changes — where the brain's auditory cortex develops abnormal spontaneous activity in the absence of external sound input, effectively generating the perception of sound internally.
Other associations — including acoustic neuroma, Ménière's disease, medication side effects (particularly certain antibiotics and NSAIDs), and neck or jaw problems.
Understanding which of these mechanisms is driving an individual's tinnitus is important — because HBOT's mechanisms of action are most directly relevant to some of them, particularly the vascular and cochlear hypoxia-related pathways.
Why the Cochlea Is So Vulnerable to Oxygen Deprivation
The inner ear, particularly the cochlea, where sound is transduced into nerve signals, is one of the most metabolically demanding and oxygen-sensitive structures in the body.
The cochlea of the inner ear is an organ that depends on adequate levels of oxygen in the blood. However, due to the protected location of the cochlea in the temporal bone, the blood supply to this organ is very limited. Blood is supplied to the cochlea mainly through the labyrinthine arteries. Cochlear hair cells have high oxygen consumption and poor tolerance to hypoxia, which is why the inner ear is prone to circulatory changes.
This anatomical vulnerability is critical. The labyrinthine artery is an end artery it has no collateral back-up supply. When its blood flow is compromised, there is no alternative route for oxygen to reach the cochlear hair cells. And those cells, once damaged by hypoxia, cannot regenerate.
Oxygen reaches the spiral organ of the cochlea in two ways: by diffusion from the vascular stria through the endolymph of the cochlear duct, and by diffusion from the space of the middle ear through the membrane of the round window. The growth occurring during HBOT in the fluids of the inner ear is accompanied by a rapid return of electrophysiological activity of the cochlea, which is crucial for its physiological activity.
This is precisely why HBOT is a logical candidate for cochlear conditions. By dissolving oxygen directly into plasma and tissue fluid at concentrations far exceeding what normal breathing achieves, HBOT can deliver oxygen to the cochlea through both of the routes described above, bypassing the compromised vascular supply and restoring the electrochemical environment the cochlear hair cells need to function.
The Strongest Evidence: HBOT for Sudden Sensorineural Hearing Loss
The condition where HBOT has the most robust evidence, and where the tinnitus connection is most direct, is sudden sensorineural hearing loss (SSNHL). Understanding this evidence is essential context for the broader tinnitus question.
As an adjunctive therapy, HBOT combined with steroids can improve hearing capacity and alleviate symptoms of tinnitus and vertigo in patients with SSNHL.
The rationale is straightforward. SSNHL is believed in many cases to result from cochlear ischaemia, a sudden reduction in blood supply to the inner ear that causes rapid hypoxic damage to the hair cells. Because the cochlea cannot regenerate its hair cells, the window for intervention is narrow. According to current scientific reports, HBOT should be implemented within two weeks after the first symptoms.
The clinical evidence bears this out. The average pure tone audiometry (PTA) score was 80.06 dB before HBOT and 60.75 dB after HBOT - a significant improvement. HBOT improved the hearing of 55.7% of patients with SSNHL.
In one particularly striking case report, a 37-year-old patient who experienced bilateral sudden hearing loss with tinnitus, who had already failed to recover with oral and intratympanic corticosteroids, was treated with HBOT. After the third session of HBOT, normal hearing returned with no tinnitus in both ears. Three months after the entire treatment, normal hearing levels were maintained.
Timing is critical, and the research is unambiguous on this point. <cite index="45">A statistically significant hearing improvement was detected in patients undergoing more than 15 cycles of HBOT at all frequencies. In the group reporting for treatment with a delay of more than 10 days, hearing improvement was statistically insignificant at higher frequencies. The statistical analysis showed that the urgent onset of HBOT could be a significant factor in the therapy of SSNHL.
The key molecular mechanisms behind these improvements have also been identified. Studies have shown that the oxygen tension in the intracochlear perilymph increases significantly during HBOT. HBOT changed serum IGF-1 and HSP70 levels in SSNHL patients - with IGF-1 (insulin-like growth factor 1) being a critical factor for cochlear hair cell survival and repair, and HSP70 (heat shock protein 70) playing a protective role against cellular stress in the inner ear.
The clinical implications are important for anyone experiencing sudden hearing loss with tinnitus: this is a medical emergency that requires urgent treatment. If you experience a sudden unexplained loss of hearing - with or without tinnitus - seek medical attention immediately and ask about HBOT within the first 72 hours if possible.
What About Chronic Tinnitus Without Acute Hearing Loss?
This is where the evidence picture becomes more nuanced - and where honesty matters.
For chronic tinnitus that has been present for months or years, without a clear acute triggering event like SSNHL, the evidence base for HBOT is less well developed. The Cochrane review and systematic analyses of HBOT for chronic tinnitus have not yet produced the kind of consistent, large-scale RCT evidence seen in other HBOT indications.
This does not mean HBOT cannot help - the mechanistic case remains coherent for several of the pathways involved in chronic tinnitus. But it does mean we should be careful about what we promise.
Where the Mechanisms Still Apply
Cochlear microcirculation. Even in chronic tinnitus, impaired blood flow to the inner ear may be a contributing factor, particularly in older adults or those with cardiovascular risk factors. HBOT's well-documented ability to stimulate angiogenesis and improve tissue oxygenation is directly relevant.
Neuroinflammation. Chronic tinnitus increasingly appears to involve aberrant activity in the central auditory system, the brain's auditory cortex developing maladaptive patterns of spontaneous firing. Neuroinflammation is now recognised as a contributor to this cortical reorganisation. HBOT's anti-inflammatory effects, reductions in TNF-α, IL-6, and NF-κB pathway activity, may address this neurological component alongside the peripheral cochlear one.
Auditory cortex plasticity. The same neuroplastic mechanisms that make HBOT relevant in stroke recovery and brain health, the upregulation of BDNF, angiogenesis in central auditory areas, and the reduction of neuroinflammation, are potentially relevant to the cortical changes that sustain chronic tinnitus. This is an area of active research rather than established evidence.
Oxidative stress and mitochondrial function. Cochlear hair cells are particularly vulnerable to oxidative stress, the accumulation of reactive oxygen species that damage cellular function. HBOT's paradoxical ability to trigger antioxidant defences while transiently raising ROS, and its stimulation of mitochondrial biogenesis, may support the metabolic health of cochlear and auditory nerve tissue in ways that conventional treatment does not.
What Types of Tinnitus Might HBOT Be Most Relevant For?
Based on the current evidence and mechanistic framework, HBOT is most likely to be relevant for:
Sudden onset tinnitus with associated hearing loss (SSNHL) — this is where the evidence is strongest and time is critical. If this applies to you, seek urgent medical attention and ask about HBOT within days, not weeks.
Tinnitus associated with acoustic trauma — noise-induced cochlear damage with an identifiable triggering event. Earlier intervention gives the best chance of limiting permanent damage.
Tinnitus in the context of vascular risk factors — particularly where small vessel disease, poor cochlear circulation, or cardiovascular disease may be contributing to inner ear hypoxia.
Tinnitus associated with post-viral illness — including long COVID, where neuroinflammation and vascular disruption may be driving auditory symptoms alongside other post-viral effects.
Tinnitus that has not responded to other approaches — for those who have tried conventional management without adequate relief, HBOT represents a mechanistically different approach worth an evidence-based conversation.
What a Consultation With OxyPlus Looks Like
If you are considering HBOT for tinnitus, the most important first step is understanding what is driving your particular case. Tinnitus is not one condition, it is a symptom with multiple causes, and the appropriateness of HBOT depends significantly on the underlying mechanism.
At OxyPlus, our Newcastle HBOT clinic, here is how we approach tinnitus:
Initial Consultation — We discuss your tinnitus history in detail: when it started, what triggered it (if known), whether it is associated with hearing loss, what investigations you have had, and what treatments you have already tried. We review your cardiovascular and general health history, as vascular factors are particularly relevant.
Honest Assessment — We will give you our honest view of whether HBOT is likely to be relevant for your specific presentation, based on the current evidence. If SSNHL is involved and you are within the treatment window, we will discuss the urgency of acting quickly. If your tinnitus is chronic and without an acute cause, we will discuss the evidence limitations clearly.
Personalised Protocol — For SSNHL, HBOT protocols typically involve 10–20 sessions at 90 minutes per session at 2 ATA. For chronic tinnitus, protocols are less standardised, we will discuss what the evidence supports based on your individual circumstances.
Coordination With Your GP — We recommend that clients with tinnitus discuss HBOT with their GP and any ENT specialist involved in their care.
We serve clients across Newcastle and the wider North East - including Gateshead, Sunderland, Durham, Northumberland, and Teesside.
An Important Note on Sudden Hearing Loss
If you or someone you know experiences a sudden, unexplained loss of hearing, particularly in one ear, with or without tinnitus or dizziness, this should be treated as a medical emergency and investigated within 24–48 hours. Do not wait to see if it resolves on its own.
SSNHL has a meaningful spontaneous recovery rate, but outcomes are significantly better with early treatment, including steroid therapy and HBOT where appropriate. The window for the most meaningful HBOT benefit is within the first 10–14 days. After that, the evidence for recovery diminishes substantially.
If you are in Newcastle or the North East and have experienced sudden hearing loss with tinnitus, call us to discuss your circumstances, we will be straightforward about whether and how urgently HBOT may be relevant.
Frequently Asked Questions
-
A: There is no established cure for tinnitus, and we would not claim HBOT is one. For tinnitus associated with sudden sensorineural hearing loss treated early, HBOT has documented success in resolving or significantly reducing both the hearing loss and the associated tinnitus. For chronic tinnitus of other causes, the evidence is more limited and we will be honest about that during your consultation.
-
A: The evidence is clear that earlier is significantly better. Ideally within 72 hours; definitely within 10–14 days. Beyond two weeks, the evidence for meaningful benefit from HBOT in SSNHL diminishes substantially. If you have experienced sudden hearing loss with tinnitus, treat it as urgent.
-
A: For SSNHL, clinical protocols typically involve 10–20 sessions at 90 minutes, 2 ATA. One patient in a published case report experienced tinnitus resolution after just three sessions. At OxyPlus Newcastle, we discuss appropriate protocols during your initial consultation based on your specific situation.
-
A: For acute noise-induced cochlear damage, including acoustic trauma from exposure to very loud sound, early HBOT may limit the extent of permanent damage by delivering oxygen to injured cochlear tissue. For long-standing noise-induced tinnitus where the hair cells are permanently damaged, the evidence is more limited, though vascular and neuroinflammatory mechanisms may still be relevant in some cases.
-
A: Tinnitus itself is not a contraindication for HBOT. However, anyone with middle ear problems (including perforated eardrum or active ear infection) should discuss this with us during consultation, as ear clearing during pressurisation requires intact ear anatomy.
-
A: OxyPlus is Newcastle's specialist HBOT clinic, offering medical-grade hyperbaric oxygen therapy with thorough clinical consultations. We serve clients across Newcastle, Gateshead, Sunderland, Durham, Northumberland, and Teesside. Visit oxyplus.co.uk to book your initial consultation.